Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study

Journal of the American Academy of DermatologyOctober 7

Open Access

n=104

Clinical Summary

View source

What was studied

Prospective multicenter, open-label study of three 1726‑nm sebum‑selective laser treatments (2–5 weeks apart) for moderate-to-severe facial acne in Fitzpatrick skin types II–VI, with outcomes assessed at 12 weeks and 52 weeks.

Key findings

Of 104 enrolled, 89 and 71 attended the 12‑ and 52‑week visits. ≥50% inflammatory lesion count improvement occurred in 79.8% at 12 weeks and 91.5% at 52 weeks; clear or almost clear IGA rose from 36.0% at 3 months to 66.2% at 52 weeks. Mild erythema (100%) and edema (98.1%) were common; no blistering, crusting, or hypo-/hyperpigmentation were observed.

Study limitations

No control group, reliance on image-based assessment, and open-label design.

Clinical implications

Three sessions of a 1726‑nm sebum‑selective laser produced sustained acne improvement through 1 year in Fitzpatrick II–VI with only transient erythema/edema and no observed pigmentary events; interpret efficacy cautiously given the uncontrolled design.